Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 51.38% | -78.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 51.38% | -78.22% | |||
| Cost of Revenue | 4.84% | 15.13% | |||
| Gross Profit | -1.36% | -69.60% | |||
| SG&A Expenses | -1.46% | 13.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.33% | 14.76% | |||
| Operating Income | -0.64% | -50.77% | |||
| Income Before Tax | 3.53% | -52.28% | |||
| Income Tax Expenses | -11.86% | 101.86% | |||
| Earnings from Continuing Operations | 3.54% | -70.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.54% | -70.36% | |||
| EBIT | -0.64% | -50.77% | |||
| EBITDA | -0.79% | -54.23% | |||
| EPS Basic | 17.39% | -64.07% | |||
| Normalized Basic EPS | 17.38% | -46.67% | |||
| EPS Diluted | 16.56% | -63.42% | |||
| Normalized Diluted EPS | 17.38% | -46.67% | |||
| Average Basic Shares Outstanding | 16.76% | 3.82% | |||
| Average Diluted Shares Outstanding | 16.76% | 3.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||